药格局 YaoGeJuCDE public lists · weekly counts
National Drug-Review Weekly
2026/01/20 – 2026/01/26
- New acceptances this week
- 371
- Drugs with new generic filings (by drug name, de-duplicated)
- 53
- Accepted this week, now under review
- 102
DefinitionAcceptance numbers accepted this week that still appear on CDE's under-review list at the data cutoff; counted by acceptance date from the daily full pull of that list, independent of snapshot history.
Drug and company names link to detail pages; sign in to view them.
New acceptances this week
By application type and drug type
371filings, 72 of them generic
By application type
| Application type | Filings |
|---|---|
| Supplement | 171 |
| New drug | 80 |
| Generic | 72 |
| Import | 34 |
| Unspecified | 10 |
| Import re-registration | 4 |
By drug type
| Drug type | Filings |
|---|---|
| Chemical drug | 224 |
| 治疗用生物制品 | 89 |
| TCM | 54 |
| Biologic | 2 |
| 体外诊断试剂 | 1 |
| 预防用生物制品 | 1 |
DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.
Most new generic filings, by drug
53 drugs with new generic filings; top 10 listed
| # | Drug | New generic filings | Filing companies | Under review, all years |
|---|---|---|---|---|
| 1 | 达格列净片 | 4 | 2 | 82 |
| 2 | 醋酸艾司利卡西平片 | 4 | 1 | 4 |
| 3 | 西诺氨酯片 | 3 | 1 | 21 |
| 4 | 培哚普利叔丁胺片 | 2 | 1 | 5 |
| 5 | 尼莫地平口服溶液 | 2 | 1 | 9 |
| 6 | 布地奈德鼻喷雾剂 | 2 | 1 | 3 |
| 7 | 沙美特罗替卡松吸入粉雾剂 | 2 | 1 | 12 |
| 8 | 盐酸去氧肾上腺素注射液 | 2 | 1 | 5 |
| 9 | 盐酸溴己新口服溶液 | 2 | 1 | 22 |
| 10 | 盐酸齐拉西酮胶囊 | 2 | 1 | 7 |
DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.
Most new acceptances, by company
211 companies with new acceptances; top 10 listed
| # | Company (first applicant) | Filings | Drugs | Generic |
|---|---|---|---|---|
| 1 | Novo Nordisk A/S | 18 | 3 | 0 |
| 2 | 陕西医药控股集团生物制品（汉中）有限公司 | 9 | 7 | 0 |
| 3 | Kashima Plant Eisai Co. Ltd. | 6 | 6 | 0 |
| 4 | Pfizer Inc. | 6 | 3 | 0 |
| 5 | 宜昌东阳光长江药业股份有限公司 | 6 | 3 | 0 |
| 6 | 江右制药（常德）有限公司 | 5 | 5 | 0 |
| 7 | 上海凯茂生物医药有限公司 | 5 | 1 | 0 |
| 8 | 山东盛迪医药有限公司 | 4 | 2 | 0 |
| 9 | 石家庄格瑞药业有限公司 | 4 | 2 | 2 |
| 10 | AstraZeneca AB | 4 | 1 | 0 |
DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.
Under-review list changes
Compared across this platform's snapshots of the under-review list
Data collected since 2026/10/22. There is not enough snapshot history for this week yet; counts of filings entering and leaving review start with the next complete week.
DefinitionEntered review = acceptance numbers seen for the first time in this platform's under-review snapshots this week, excluding the baseline records of the first snapshot day (2026/10/22). Left review = acceptance numbers whose last snapshot sighting falls in this week and that this snapshot no longer lists; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.
Class 3 and new-drug acceptances
135 this week
| Accepted | Drug | Applicants |
|---|---|---|
| 2026/01/26Generic · Class 3 | 注射用兰索拉唑CYHS2600280 | 山西德元堂药业有限公司 |
| 2026/01/26Generic · Class 3 | 小儿复方氨基酸注射液（20AA）CYHS2600276 | 山东齐都药业有限公司 |
| 2026/01/26New drug · Class 1 | BG-A3004注射液CXSL2600129 | 广州百济神州生物制药有限公司 |
| 2026/01/26New drug · Class 1 | EA5注射液皮下制剂CXSL2600126 | 山东览屹医药科技有限公司; 上海览屹医药科技有限公司 |
| 2026/01/26New drug · Class 2.1;2.2 | 泰它西普注射液CXSL2600125 | 荣昌生物制药（烟台）股份有限公司 |
| 2026/01/26New drug · Class 1 | BCR-0003片CXHL2600123 | 浙江众神创新医药科技有限公司 |
| 2026/01/26New drug · Class 1 | BCR-0003片CXHL2600122 | 浙江众神创新医药科技有限公司 |
| 2026/01/26New drug · Class 1 | DC561043片CXHL2600121 | 中国科学院上海药物研究所; 临港国家实验室 |
| 2026/01/24Generic · Class 3 | 醋酸艾司利卡西平片CYHS2600270 | 上海上药中西制药有限公司; 常州制药厂有限公司 |
| 2026/01/24Generic · Class 3 | 醋酸艾司利卡西平片CYHS2600269 | 上海上药中西制药有限公司; 常州制药厂有限公司 |
| 2026/01/24Generic · Class 3 | 醋酸艾司利卡西平片CYHS2600268 | 上海上药中西制药有限公司; 常州制药厂有限公司 |
| 2026/01/24Generic · Class 3 | 醋酸艾司利卡西平片CYHS2600267 | 上海上药中西制药有限公司; 常州制药厂有限公司 |
| 2026/01/24New drug · Class 1 | RSS0393乳胶CXHL2600120 | 瑞石生物医药有限公司 |
| 2026/01/24New drug · Class 1 | RSS0393乳胶CXHL2600119 | 瑞石生物医药有限公司 |
| 2026/01/24New drug · Class 1 | RSS0393乳胶CXHL2600118 | 瑞石生物医药有限公司 |
| 2026/01/24New drug · Class 1 | SYH2069注射液CXHL2600117 | 北京抗创联生物制药技术研究有限公司; 石药集团欧意药业有限公司 |
| 2026/01/24New drug · Class 1 | SYH2069注射液CXHL2600116 | 北京抗创联生物制药技术研究有限公司; 石药集团欧意药业有限公司 |
| 2026/01/24New drug · Class 1 | SYH2069注射液CXHL2600115 | 北京抗创联生物制药技术研究有限公司; 石药集团欧意药业有限公司 |
| 2026/01/24New drug · Class 1 | ACC085注射液CXHL2600114 | 江苏艾迪药业集团股份有限公司; 泸州艾迪医药技术有限公司 |
| 2026/01/24New drug · Class 1 | HSK47388片（I）CXHL2600113 | 海思科医药集团股份有限公司 |
| 2026/01/24New drug · Class 1 | HSK47388片（I）CXHL2600112 | 海思科医药集团股份有限公司 |
| 2026/01/23Import · Class 1 | PF-08634404JXSL2600024 | Pfizer Inc.; Pfizer (Beijing) Research and Development Co. Ltd. |
| 2026/01/23Import · Class 1 | PF-08634404JXSL2600023 | Pfizer Inc.; Pfizer (Beijing) Research and Development Co. Ltd. |
| 2026/01/23Import · Class 1 | Bleximenib片JXHL2600029 | Stichting Hemato-Oncologie voor Volwassenen Nederland; PPD Pharmaceutical Development (Beijing) Co. Ltd |
| 2026/01/23Import · Class 1 | Bleximenib片JXHL2600028 | Stichting Hemato-Oncologie voor Volwassenen Nederland; PPD Pharmaceutical Development (Beijing) Co. Ltd |
| 2026/01/23Import · Class 1 | HTT227片JXHL2600027 | Novartis Pharma AG; China Novartis Institutes for BioMedical Research Co. Ltd. |
| 2026/01/23Generic · Class 3 | 吡拉西坦注射液CYHS2600266 | 以岭万洲国际制药有限公司 |
| 2026/01/23Generic · Class 3 | 盐酸去氧肾上腺素注射液CYHS2600259 | 绪必迪药业（沧州）有限公司; 河北凯威制药有限责任公司 |
| 2026/01/23Generic · Class 3 | 盐酸去氧肾上腺素注射液CYHS2600258 | 绪必迪药业（沧州）有限公司; 河北凯威制药有限责任公司 |
| 2026/01/23New drug · Class 1.1 | 丹元糖痹软膏CXZL2600012 | 杏林中医药科技（广州）有限公司 |
105 more not listed (at most 30 rows).
DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.
Subscribe to the weekly
No account needed.
The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.